Last reviewed · How we verify
PD-1
PD-1 inhibitors block the programmed death-1 checkpoint on immune cells, allowing T cells to recognize and attack cancer cells.
PD-1 inhibitors block the programmed death-1 checkpoint on immune cells, allowing T cells to recognize and attack cancer cells. Used for Advanced or metastatic solid tumors (specific indication under investigation in phase 3 trial).
At a glance
| Generic name | PD-1 |
|---|---|
| Also known as | SCT-I10A, Toripalimab, PD-1 inhibitor, immunotherapy, apatinib |
| Sponsor | Tianjin Medical University Second Hospital |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
PD-1 is an immune checkpoint protein that normally acts as a 'brake' on the immune system. Cancer cells exploit this by expressing PD-L1, which binds PD-1 and suppresses anti-tumor immunity. PD-1 inhibitors prevent this interaction, restoring T cell activation and enabling durable anti-tumor responses. This mechanism has proven effective across multiple solid and hematologic malignancies.
Approved indications
- Advanced or metastatic solid tumors (specific indication under investigation in phase 3 trial)
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Immune-related pneumonitis
- Immune-related hepatitis
- Immune-related colitis
Key clinical trials
- BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
- Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy (PHASE1)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I) (PHASE1)
- BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia (PHASE2)
- A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors) (PHASE1)
- Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PD-1 CI brief — competitive landscape report
- PD-1 updates RSS · CI watch RSS
- Tianjin Medical University Second Hospital portfolio CI